Keywords: fda, further, delays, roche, actemra, over, fears
FDA further delays Roche's Actemra over fears the drug may affect natal development and fertility
Article | 15 December 2008
Basel, Switzerland-headquartered drug major Roche is facing delays for the US approval of its potential blockbuster novel interleukin-6 receptor-inhibiting monoclonal ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Novo Nordisk's diabetes drug Victoza produced 8% weight loss in Ph III obesity trial
- Proposal to list Roche's Neulastim and Actemra in New Zealand
- Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
- Positive new data on Novartis' Galvus in elderly type 2 diabetes patients
- Johnson & Johnson expects 10 NDA filings by 2017, saying pharma sector poised for growth
